Cargando…

Tivozanib in renal cell carcinoma: a systematic review of the evidence and its dissemination in the scientific literature

BACKGROUND: Tivozanib (Fotivda) is an anti-angiogenic tyrosine kinase inhibitor that was denied access to the US market by the Food and Drug Administration (FDA). In contrast, it was granted approval by the European Medicines Agency (EMA) for the treatment of Renal Cell Carcinoma in adults. Given th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caquelin, Laura, Gewily, Mohamed, Mottais, Wendy, Tebaldi, Chloé, Laviolle, Bruno, Naudet, Florian, Locher, Clara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994226/ https://www.ncbi.nlm.nih.gov/pubmed/35397511 http://dx.doi.org/10.1186/s12885-022-09475-7

Ejemplares similares

Tivozanib in the treatment of renal cell carcinoma
por: Hepgur, Mehmet, et al.
Publicado: (2013)

Data-sharing and re-analysis for main studies assessed by the European Medicines Agency—a cross-sectional study on European Public Assessment Reports
por: Siebert, Maximilian, et al.
Publicado: (2022)

Tivozanib for the treatment of renal cell carcinoma: patient selection and perspectives
por: Rodenburg, RJ, et al.
Publicado: (2019)

Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma
por: Cowey, C Lance
Publicado: (2013)

Impact of tivozanib on patient outcomes in treatment of advanced renal cell carcinoma
por: Yalcin, Suayib, et al.
Publicado: (2019)

Current Status of Tivozanib in the Treatment of Patients With Advanced Renal Cell Carcinoma
por: Sakellakis, Minas, et al.
Publicado: (2023)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Tivozanib in renal cell carcinoma: a new approach to previously treated disease
por: Salgia, Nicholas J., et al.
Publicado: (2020)

Milestones for development of tivozanib for kidney cancer therapy
por: Crescentini, Robert, et al.
Publicado: (2012)

Evaluation in alcohol use disorders – insights from the nalmefene experience
por: Naudet, Florian, et al.
Publicado: (2016)

Risks and Benefits of Nalmefene in the Treatment of Adult Alcohol Dependence: A Systematic Literature Review and Meta-Analysis of Published and Unpublished Double-Blind Randomized Controlled Trials
por: Palpacuer, Clément, et al.
Publicado: (2015)

Tivozanib: a novel VGFR inhibitor for kidney cancer
por: Boyle, Helen
Publicado: (2013)

Assessing the magnitude of changes from protocol to publication—a survey on Cochrane and non-Cochrane Systematic Reviews
por: Siebert, Maximilian, et al.
Publicado: (2023)

Letter to the editor: Covid-19 and Vit-D: Disease mortality negatively correlates with sunlight exposure
por: Naudet, Florian, et al.
Publicado: (2020)

Data-sharing recommendations in biomedical journals and randomised controlled trials: an audit of journals following the ICMJE recommendations
por: Siebert, Maximilian, et al.
Publicado: (2020)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated with Axitinib: Subgroup Analysis from TIVO-3
por: Meza, Luis, et al.
Publicado: (2022)

Could tivozanib be a new potent pan-VEGF inhibitor in RCC therapy?
por: Mihály, Zsuzsanna, et al.
Publicado: (2012)

Mechanism Underlying Triple VEGFR Inhibitor Tivozanib-Induced Hypertension in Mice Model
por: Alanazi, Wael A., et al.
Publicado: (2023)

Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study
por: Molina, Ana M., et al.
Publicado: (2018)

Vibration of effects from diverse inclusion/exclusion criteria and analytical choices: 9216 different ways to perform an indirect comparison meta-analysis
por: Palpacuer, Clément, et al.
Publicado: (2019)

Does reductio ad absurdum have a place in evidence-based medicine?
por: Naudet, Florian, et al.
Publicado: (2014)

Towards new treatment options for renal cell carcinoma: development and clinical results of tivozanib, a selective VEGFR tyrosine kinase inhibitor
por: Eskens, Ferry ALM, et al.
Publicado: (2012)

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial
por: Barata, Pedro C, et al.
Publicado: (2023)

Tivozanib: is total VEGFR inhibition the way to success in terms of tolerability and efficacy in advanced kidney cancer?
por: Gross-Goupil, Marine, et al.
Publicado: (2012)

A multicentre phase 1b/2 study of tivozanib in patients with advanced inoperable hepatocellular carcinoma
por: Fountzilas, Christos, et al.
Publicado: (2020)

A survey of biomedical journals to detect editorial bias and nepotistic behavior
por: Scanff, Alexandre, et al.
Publicado: (2021)

Correction: A survey of biomedical journals to detect editorial bias and nepotistic behavior
por: Scanff, Alexandre, et al.
Publicado: (2022)

Aripiprazole in the Maintenance Treatment of Bipolar Disorder: A Critical Review of the Evidence and Its Dissemination into the Scientific Literature
por: Tsai, Alexander C., et al.
Publicado: (2011)

Anti-tumour activity of tivozanib, a pan-inhibitor of VEGF receptors, in therapy-resistant ovarian carcinoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Blockade of vascular endothelial growth factor receptors by tivozanib has potential anti-tumour effects on human glioblastoma cells
por: Momeny, Majid, et al.
Publicado: (2017)

Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study
por: Westerman, Mary E., et al.
Publicado: (2020)

Deepfakes and scientific knowledge dissemination
por: Doss, Christopher, et al.
Publicado: (2023)

Mega randomized clinical trials: a definitive solution or a double-edged sword?
por: Lemaitre, Florian, et al.
Publicado: (2021)

The evidence base for psychotropic drugs approved by the European Medicines Agency: a meta-assessment of all European Public Assessment Reports
por: Erhel, Florian, et al.
Publicado: (2020)

Tivozanib mediated inhibition of c-Kit/SCF signaling on Tregs and MDSCs and reversal of tumor induced immune suppression correlates with survival of HCC patients
por: Kalathil, Suresh Gopi, et al.
Publicado: (2020)

At your service! Publishing and dissemination of scientific research
por: Hallberg, Lillemor
Publicado: (2012)

Mythical Thinking, Scientific Discourses and Research Dissemination
por: Hroar Klempe, Sven
Publicado: (2011)

Dissemination of scientific software with Galaxy ToolShed
por: Blankenberg, Daniel, et al.
Publicado: (2014)

The influence of Iranian scientific journals in disseminating medical information
por: Aminpour, Farzaneh
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_2o9jt90lddunr5fslqhsml57nm